Daiichi Sankyo Company マネジメント

マネジメント基準チェック /34

Daiichi Sankyo Companyの CEO はHiroyuki Okuzawaで、 Apr2023年に任命され、の在任期間は 3.08年です。の年間総報酬は¥ 252.00Mで、 33.3%給与と66.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.003%を直接所有しており、その価値は$ 865.82K 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と2.4年です。

主要情報

Hiroyuki Okuzawa

最高経営責任者

JP¥252.0m

報酬総額

CEO給与比率	33.33%
CEO在任期間	3.1yrs
CEOの所有権	0.003%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	2.4yrs

経営陣の近況

Recent updates

CEO報酬分析

Daiichi Sankyo Company の収益と比較して、Hiroyuki Okuzawa の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2026	n/a	n/a	JP¥260b
Dec 31 2025	n/a	n/a	JP¥305b
Sep 30 2025	n/a	n/a	JP¥280b
Jun 30 2025	n/a	n/a	JP¥296b
Mar 31 2025	JP¥252m	JP¥84m	JP¥296b
Dec 31 2024	n/a	n/a	JP¥246b
Sep 30 2024	n/a	n/a	JP¥250b
Jun 30 2024	n/a	n/a	JP¥229b
Mar 31 2024	JP¥252m	JP¥84m	JP¥201b
Dec 31 2023	n/a	n/a	JP¥186b
Sep 30 2023	n/a	n/a	JP¥148b
Jun 30 2023	n/a	n/a	JP¥147b
Mar 31 2023	JP¥151m	JP¥51m	JP¥109b

報酬と市場: Hiroyukiの総報酬 ($USD 1.59M ) は、 US市場 ($USD 14.79M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Hiroyukiの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Hiroyuki Okuzawa (63 yo)

3.1yrs

在職期間

JP¥252,000,000

報酬

Mr. Hiroyuki Okuzawa is Chief Executive Officer of Daiichi Sankyo Company, Limited from April 1, 2025 and was its Chief Operating Officer until April 1, 2025. He is President of Daiichi Sankyo Company, Lim...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sunao Manabe	Executive Chairperson	11.9yrs	JP¥342.00m	0.0092% $ 2.9m
Hiroyuki Okuzawa	President	3.1yrs	JP¥252.00m	0.0028% $ 865.8k
Tomohiro Kodama	Senior Executive Officer	less than a year	データなし	データなし
Tetsuya Ohira	Corporate Officer	less than a year	データなし	データなし
Naoto Tsukaguchi	Senior Executive Officer	no data	データなし	データなし
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	2.3yrs	データなし	データなし
Takashi Matsumoto	Sr. Exec Ofcr	4.3yrs	データなし	0.0025% $ 763.8k
Joji Nakayama	Senior Adviser	5.9yrs	JP¥185.00m	データなし
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	no data	データなし	データなし
Stuart Mackey	Global Head of Business Development	no data	データなし	データなし
Thierry Gruson	Head of Global Oncology Marketing	no data	データなし	データなし
Kento Wada	Global Head of Clinical Safety & Pharmacovigilance Unit	no data	データなし	データなし

2.7yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: DSKY.Fの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sunao Manabe	Executive Chairperson	11.9yrs	JP¥342.00m	0.0092% $ 2.9m
Hiroyuki Okuzawa	President	4.9yrs	JP¥252.00m	0.0028% $ 865.8k
Takashi Matsumoto	Sr. Exec Ofcr	1.9yrs	データなし	0.0025% $ 763.8k
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	1.3yrs	データなし	データなし
Shizuko Ueno	Senior Executive Officer	1.3yrs	データなし	データなし
Reiko Kinoshita	Independent Outside Director	less than a year	データなし	データなし
Akihiro Hiroshi Watanabe	Independent Outside Director	less than a year	データなし	データなし
Yo Honma	Independent Outside Director	1.9yrs	データなし	0.000050% $ 15.5k
Takaaki Nishii	Independent Outside Chairperson	2.9yrs	データなし	0.00016% $ 49.5k
Miyuki Arai	Full-time Member of Audit & Supervisory Board	2.9yrs	データなし	0.0011% $ 355.6k
Yukiko Imazu	Outside Audit & Supervisory Board Member	7.9yrs	データなし	データなし
Yasuhiro Komatsu	Independent Outside Director	3.9yrs	データなし	データなし

2.4yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: DSKY.Fの取締役会は経験豊富ではない ( 2.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/26 07:30
終値	2026/05/22 00:00
収益	2026/03/31
年間収益	2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Daiichi Sankyo Company, Limited 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。27

アナリスト	機関
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Daiichi Sankyo Company マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Recent updates

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Suntory Holdings Limited signed a letter of intent to acquire Daiichi Sankyo Healthcare Co., Ltd. from Daiichi Sankyo Company, Limited (TSE:4568) for approximately ¥250 billion.

Daiichi Sankyo Company, Limited to Report Q4, 2026 Results on Apr 27, 2026

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Datroway Approves in Us for EGFRm Lung Cancer

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 17,000,000 shares, representing 0.91% for ¥50,000 million.

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited Provides Updated on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Daiichi Sankyo's Datopotamab Deruxtecan is Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd)

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

マネジメント基準チェック /34